Despite promising clinical results, copyright's Vyndamax, a treatment for hereditary transthyretin-mediated amyloidosis (hATTR), is encountering considerable resistance from managed care entities. Such companies are https://murraypjjj935100.estate-blog.com/40812758/company-s-vyndamax-faces-is-encountering-pharmacy-benefit-manager-challenges-a-look-at-reimbursement-disputes